TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31267980

Group type: EXPERIMENTAL
Intervention: Mobile phone-based mental health intervention (1 month of support from a coach, up to 3 brief phone sessions, text messaging, and mobile mental health apps)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Mobile phone-based mental health intervention
Number of subjects: 35
Study: 31268374

Group type: EXPERIMENTAL
Intervention: Subcutaneous immunoglobulin 20%
Number of subjects: 0
Study: 31268513

Group type: EXPERIMENTAL
Intervention: Core/lower limb muscle thickness assessment
Number of subjects: 68

Group type: COMPARATOR
Intervention: Balance assessment using force platform system
Number of subjects: 68

Group type: COMPARATOR
Intervention: Knee proprioception sense assessment
Number of subjects: 68

Group type: COMPARATOR
Intervention: Muscle thickness assessment
Number of subjects: 68
Study: 31269208

Group type: EXPERIMENTAL
Intervention: Raltegravir (400 mg twice daily) / Etravirine (200 mg twice daily)
Number of subjects: 165
Study: 31269546

Group type: EXPERIMENTAL
Intervention: Vosoritide 2.5 μg/kg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Vosoritide 7.5 μg/kg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Vosoritide 15.0 μg/kg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Vosoritide 30.0 μg/kg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Vosoritide (all doses)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Vosoritide (up to 15.0 μg/kg)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Vosoritide (15.0 and 30.0 μg/kg)
Number of subjects: 35
Study: 31269854

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31269910

Group type: EXPERIMENTAL
Intervention: Monocytic HLA-DR (mHLA-DR) expression, interleukin 6 (IL-6), interleukin 10 (IL-10), tumor necrosis factor alpha (TNF-alpha), lipopolysaccharide-binding protein (LBP)
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Interleukin 6 (IL-6) levels on day 1
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Stroke-associated pneumonia (SAP)
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Monocytic HLA-DR (mHLA-DR) expression
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: National Institute of Health Stroke Scale (NIHSS) score
Number of subjects: 486
Study: 31269923

Group type: EXPERIMENTAL
Intervention: Complete immunological profile using classical descriptive immune phenotyping and TruCulture®
Number of subjects: 630
Study: 31269978

Group type: EXPERIMENTAL
Intervention: Foam sclerotherapy
Number of subjects: 160

Group type: COMPARATOR
Intervention: Ambulatory phlebectomies
Number of subjects: 160
Study: 31270080

Group type: EXPERIMENTAL
Intervention: PTPN2-deleted T-ALL
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: PTPN2-deleted pediatric cases
Number of subjects: 430

Group type: COMPARATOR
Intervention: PTPN2-deleted adult cases
Number of subjects: 430
Study: 31270103

Group type: EXPERIMENTAL
Intervention: DARA-MD 1200 mg
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: DARA-MD 1800 mg
Number of subjects: 53
Study: 31270178

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 30-s STS test
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 6-min walk test (6MWT)
Number of subjects: 96
Study: 31270738

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD) therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel risk score model for primary prevention of SCD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Current ICD indications according to international Consensus Statement
Number of subjects: 0
Study: 31270774

Group type: EXPERIMENTAL
Intervention: Active therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 31271463

Group type: EXPERIMENTAL
Intervention: Maternal tenofovir treatment during the third trimester
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control (no tenofovir treatment)
Number of subjects: 201
Study: 31272391

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Number of subjects: 20
Study: 31272402

Group type: EXPERIMENTAL
Intervention: Maternity waiting homes (MWHs)
Number of subjects: 2381
Study: 31272487

Group type: EXPERIMENTAL
Intervention: Mobile phone-based reminders
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Mobile phone-based reminders and incentives (conditional financial transfers)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Standard of care (no reminders or incentives)
Number of subjects: 400
Study: 31272485

Group type: EXPERIMENTAL
Intervention: Transthoracic esophagectomy with at least 2-field lymphadenectomy
Number of subjects: 5000
Study: 31272548

Group type: EXPERIMENTAL
Intervention: Aortic Valve Replacement (AVR)
Number of subjects: 23528
Study: 31272934

Group type: EXPERIMENTAL
Intervention: Lumen apposing metal stents (LAMS)
Number of subjects: 192
Study: 31273088

Group type: EXPERIMENTAL
Intervention: Eltrombopag, an oral thrombopoietin-mimetic, dosage and duration not specified
Number of subjects: 24
Study: 31273510

Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal persons (control group)
Number of subjects: 20
Study: 31273686

Group type: EXPERIMENTAL
Intervention: tenofovir/emtricitabine + lopinavir/ritonavir (TDF/FTC LPV/r; arm A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: abacavir + didanosine + lopinavir/ritonavir (arm B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: tenofovir/emtricitabine + darunavir/ritonavir (arm C)
Number of subjects: 0
Study: 31273942

Group type: EXPERIMENTAL
Intervention: Baseline seropositive women
Number of subjects: 2687
Study: 31274114

Group type: EXPERIMENTAL
Intervention: PARTNER intervention (4-session motivational interviewing-based intervention with video-based communication training)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Attention-matched psychoeducation control arm
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Biological markers for drug use
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Biological markers for sexual HIV transmission risk
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Biological markers for PrEP adherence
Number of subjects: 240
Study: 31274544

Group type: EXPERIMENTAL
Intervention: 5-HTTLPR SS genotype (rs4795541) in Cohort A
Number of subjects: 2773

Group type: EXPERIMENTAL
Intervention: 5-HTTLPR SS genotype (rs4795541) in Cohort B
Number of subjects: 2773

Group type: EXPERIMENTAL
Intervention: Female sex in Cohort A
Number of subjects: 2773

Group type: EXPERIMENTAL
Intervention: Nonsmoking status in Cohort A
Number of subjects: 2773

Group type: EXPERIMENTAL
Intervention: Patient age in Cohort A
Number of subjects: 2773
Study: 31275098

Group type: EXPERIMENTAL
Intervention: Sleep extension
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no sleep extension)
Number of subjects: 0
Study: 31275206

Group type: EXPERIMENTAL
Intervention: Vocational integration programs for mentally burdened emerging adults
Number of subjects: 0
Study: 31275432

Group type: EXPERIMENTAL
Intervention: Early coronary intervention
Number of subjects: 162

Group type: COMPARATOR
Intervention: Delayed coronary intervention
Number of subjects: 162
Study: 31276005

Group type: EXPERIMENTAL
Intervention: Conservative treatment for ATR
Number of subjects: 34
Study: 31276156

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) surgery
Number of subjects: 8
Study: 31276163

Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg) IV every 2 weeks
Number of subjects: 10
Study: 31277626

Group type: EXPERIMENTAL
Intervention: Combined respiratory support (CRS) using high frequency jet ventilation (HFJV) and small volume mechanical ventilation (SVMV)
Number of subjects: 38

Group type: COMPARATOR
Intervention: General anesthesia with mechanical ventilation (MV)
Number of subjects: 38
Study: 31277699

Group type: EXPERIMENTAL
Intervention: MK-2206 (AKT inhibitor)
Number of subjects: 27
Study: 31277722

Group type: EXPERIMENTAL
Intervention: Sedatives only
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Opioids only
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Sedatives plus opioids
Number of subjects: 79

Group type: COMPARATOR
Intervention: No drugs
Number of subjects: 79
Study: 31277780

Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Standard-dose computed tomography (SDCT)
Number of subjects: 256
Study: 31277975

Group type: EXPERIMENTAL
Intervention: AVXS-101 (onasemnogene abeparvovec)
Number of subjects: 12
Study: 31278103

Group type: COMPARATOR
Intervention: Serum Vitamin B levels
Number of subjects: 1829
Study: 31278577

Group type: EXPERIMENTAL
Intervention: MRE
Number of subjects: 100

Group type: COMPARATOR
Intervention: TE
Number of subjects: 100

Group type: COMPARATOR
Intervention: pSWE
Number of subjects: 100
Study: 31278692

Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa (1200 mg every 2 weeks)
Number of subjects: 644
Study: 31278892

Group type: EXPERIMENTAL
Intervention: Hypertensive cohort
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Intervention on renal artery
Number of subjects: 71
Study: 31278925

Group type: EXPERIMENTAL
Intervention: Compensatory strategies
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Caregiver strategies
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Caregiver education
Number of subjects: 168
Study: 31279240

Group type: EXPERIMENTAL
Intervention: Chronic migraine (CM) patients during spontaneous headache attack (ictal phase)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Episodic migraine (EM) patients during spontaneous headache attack (ictal phase)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Healthy controls (HC) during spontaneous headache attack (ictal phase)
Number of subjects: 15
Study: 31279304

Group type: EXPERIMENTAL
Intervention: Ibrutinib (560 mg/day) until disease progression or unacceptable toxicity
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Ibrutinib (560 mg/day)
Number of subjects: 52
Study: 31279564

Group type: EXPERIMENTAL
Intervention: MenACWY-CRM (4 doses during infancy)
Number of subjects: 203

Group type: COMPARATOR
Intervention: MenACWY-CRM (2 doses at 12/13 and 15 months or 1 dose at 18 months)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: MenACWY-CRM booster dose at 60 months
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: MenACWY-CRM (booster dose)
Number of subjects: 203
Study: 31279752

Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic cell transplant
Number of subjects: 17
Study: 31279871

Group type: EXPERIMENTAL
Intervention: Vedolizumab (300 mg intravenously at weeks 0, 2, and 6, then every 8 weeks thereafter for 26 weeks)
Number of subjects: 101
Study: 31280076

Group type: EXPERIMENTAL
Intervention: Overweight patients (BMI 25-<30)
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: BMI at baseline
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Weight gain during the study
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Higher initial increase in BMI
Number of subjects: 811
Study: 31280289

Group type: EXPERIMENTAL
Intervention: 3D machine learning derived models of wall thickness pre-AVR and 1 year post-AVR
Number of subjects: 116

Group type: COMPARATOR
Intervention: Patients without LVH (16% with normal indexed LV mass, 79% female)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Post-AVR changes in NT-proBNP
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Post-AVR changes in systolic blood pressure
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Correlation of NT-proBNP with percentage LV mass regression in males
Number of subjects: 116
Study: 31280362

Group type: EXPERIMENTAL
Intervention: Erdafitinib (doses ranging from 0.5 to 12 mg, with a highest therapeutic dose of 9 mg daily)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Erdafitinib (concentration-QTc analysis)
Number of subjects: 187
Study: 31280390

Group type: EXPERIMENTAL
Intervention: LdT + ADV/TDF
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: LdT
Number of subjects: 31
Study: 31280918

Group type: EXPERIMENTAL
Intervention: Positive Psychology Intervention (PPI)
Number of subjects: 128
Study: 31281675

Group type: EXPERIMENTAL
Intervention: Right ventricular pacing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 31282539

Group type: EXPERIMENTAL
Intervention: Measles vaccination (CAM-70) at 6 and 12 months of age
Number of subjects: 283
Study: 31282597

Group type: EXPERIMENTAL
Intervention: miR-558, miR-146a, miR-150, miR-124, and miR-143 expression levels
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: IL-6, TNF-α, and COX-2 levels
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Pain thresholds
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Gender differences in miRNA expression
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Inflammatory markers (IL-6, TNF-α, COX-2)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Ability to enjoy life and relations with others
Number of subjects: 150
Study: 31282758

Group type: EXPERIMENTAL
Intervention: Nintedanib plus docetaxel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31283841

Group type: EXPERIMENTAL
Intervention: Childhood absence epilepsy (CAE)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 17
Study: 31283919

Group type: EXPERIMENTAL
Intervention: CT imaging subtypes with visual and quantitative features
Number of subjects: 9080

Group type: EXPERIMENTAL
Intervention: Quantitative but not visual emphysema
Number of subjects: 9080

Group type: EXPERIMENTAL
Intervention: Visual but not quantitative emphysema
Number of subjects: 9080

Group type: EXPERIMENTAL
Intervention: PSE and/or moderate to severe CLE
Number of subjects: 9080
Study: 31284072

Group type: EXPERIMENTAL
Intervention: Patent Blue injection into different parts of the pancreas
Number of subjects: 14
Study: 31284680

Group type: EXPERIMENTAL
Intervention: Aerosol with active heated humidification at 10 L/min
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Aerosol with active heated humidification at 30 L/min
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Aerosol with active heated humidification at 50 L/min
Number of subjects: 23

Group type: COMPARATOR
Intervention: Aerosol with unheated oxygen at 10 L/min
Number of subjects: 23

Group type: COMPARATOR
Intervention: Aerosol with unheated oxygen at 30 L/min
Number of subjects: 23

Group type: COMPARATOR
Intervention: Aerosol with unheated oxygen at 50 L/min
Number of subjects: 23
Study: 31285068

Group type: EXPERIMENTAL
Intervention: CKD in diabetic patients
Number of subjects: 3045

Group type: EXPERIMENTAL
Intervention: CKD in nondiabetic patients
Number of subjects: 3045

Group type: EXPERIMENTAL
Intervention: End-stage renal disease in diabetic patients
Number of subjects: 3045
Study: 31285375

Group type: EXPERIMENTAL
Intervention: Early stenting (≤14 days)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Late stenting (>14 days)
Number of subjects: 115
Study: 31285522

Group type: EXPERIMENTAL
Intervention: Short sleep duration (< 8h/day)
Number of subjects: 3211

Group type: COMPARATOR
Intervention: Long sleep duration (≥ 10h/day)
Number of subjects: 3211
Study: 31285780

Group type: EXPERIMENTAL
Intervention: 150 minutes per week of aerobic exercise
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: 300 minutes per week of aerobic exercise
Number of subjects: 400

Group type: COMPARATOR
Intervention: Moderate volume of aerobic exercise (150 min/week)
Number of subjects: 400

Group type: COMPARATOR
Intervention: High volume of aerobic exercise (300 min/week)
Number of subjects: 400
Study: 31285871

Group type: EXPERIMENTAL
Intervention: Hyperthermic intrapleural chemotherapy (HITHOC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Talc pleurodesis (TALC)
Number of subjects: 40
Study: 31285876

Group type: EXPERIMENTAL
Intervention: Sublobar resection
Number of subjects: 1579

Group type: COMPARATOR
Intervention: Lobectomy
Number of subjects: 1579
Study: 31286111

Group type: EXPERIMENTAL
Intervention: Follow-up after 10 to 12 years
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Reducing stress levels
Number of subjects: 166
Study: 31286197

Group type: EXPERIMENTAL
Intervention: Infrapopliteal drug-coated balloon angioplasty with the ELUTAX SV DCB
Number of subjects: 164
Study: 31286333

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 41
Study: 31286884

Group type: EXPERIMENTAL
Intervention: Single Frequency Bioelectrical Impedance Analysis (SFBIA)
Number of subjects: 228

Group type: COMPARATOR
Intervention: BCRL group (n=22)
Number of subjects: 228
Study: 31286890

Group type: EXPERIMENTAL
Intervention: High MP (Mallampati III/IV)
Number of subjects: 584

Group type: COMPARATOR
Intervention: Low MP (Mallampati I/II)
Number of subjects: 584
Study: 31286994

Group type: EXPERIMENTAL
Intervention: SCD-community
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: SCD-clinic
Number of subjects: 78

Group type: COMPARATOR
Intervention: HC
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Both SCD groups
Number of subjects: 78
Study: 31287387

Group type: EXPERIMENTAL
Intervention: Perfluorobutane-enhanced ultrasound (US) combined with conventional B-mode US
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional B-mode ultrasound (US)
Number of subjects: 0
Study: 31288365

Group type: EXPERIMENTAL
Intervention: Intravenous indocyanine green (5 mg/kg) 24 hours before metastasectomy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: NIR imaging during video-assisted thoracic surgery metastasectomy
Number of subjects: 30
Study: 31288565

Group type: EXPERIMENTAL
Intervention: hsTnT (high-sensitivity troponin T) drawn at baseline and 3 hours
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: hsTnT values below the 99th percentile
Number of subjects: 499
Study: 31288863

Group type: EXPERIMENTAL
Intervention: Sufentanil infusion
Number of subjects: 20
Study: 31289029

Group type: EXPERIMENTAL
Intervention: Autologous T cells engineered to express an affinity-enhanced T-cell receptor (TCR) recognizing NY-ESO-1 and LAGE-1
Number of subjects: 25
Study: 31289048

Group type: EXPERIMENTAL
Intervention: Diabetes-related self-care activities (DRSCA)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Resilience
Number of subjects: 246
Study: 31289075

Group type: EXPERIMENTAL
Intervention: Symptom Navi© Programme (SN©P) - nurse-led intervention with at least two semistructured consultations and SN©Flyers.
Number of subjects: 140

Group type: COMPARATOR
Intervention: Usual care group (control).
Number of subjects: 140
Study: 31289090

Group type: EXPERIMENTAL
Intervention: Early parenteral nutrition (PN) during the first 7 postnatal days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 31289238

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA injection (100 units)
Number of subjects: 13
Study: 31289819

Group type: EXPERIMENTAL
Intervention: Genetic predictors of ganglion cell/inner plexiform layer atrophy
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: Genetic predictors of sustained loss of 5-letters in low-contrast letter acuity
Number of subjects: 582
Study: 31290084

Group type: EXPERIMENTAL
Intervention: Multimodal analgesia protocol (paracetamol, oxycodone, methoxyflurane)
Number of subjects: 200
Study: 31290107

Group type: EXPERIMENTAL
Intervention: Laparoscopic Sleeve Gastrectomy (LSG)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Roux-en-Y Gastric Bypass (RYGB)
Number of subjects: 57
Study: 31290405

Group type: EXPERIMENTAL
Intervention: SMS reminders only
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: SMS reminders plus 150 KES incentive
Number of subjects: 537

Group type: COMPARATOR
Intervention: Control
Number of subjects: 537
Study: 31290406

Group type: EXPERIMENTAL
Intervention: VR Personality Project
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Web-based GM intervention
Number of subjects: 159

Group type: COMPARATOR
Intervention: Active Web-based control
Number of subjects: 159
Study: 31291010

Group type: EXPERIMENTAL
Intervention: HPV vaccine intent
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Provider recommendation for the HPV vaccine
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Positive general attitude toward vaccines
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Perceived severity of HPV disease
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Vaccine intent
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Age of survivors
Number of subjects: 103
Study: 31291057

Group type: EXPERIMENTAL
Intervention: Early antiretroviral therapy (E-ART); provided to 105 FSWs; retention at end of study: 59.0% (62/105); mean duration of follow-up: 13.4 (±7.9) months; self-reported adherence over 90%.
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Pre-exposure prophylaxis (PrEP); provided to 256 FSWs; retention at end of study: 47.3% (121/256); mean duration of follow-up: 11.8 (±7.9) months; adherence decreased from 78.4% to 56.7% (p-trend < 0.0001).
Number of subjects: 442
Study: 31291801

Group type: EXPERIMENTAL
Intervention: Device-integrated diagnostic parameters including fluid index flag, atrial fibrillation flag, and activity flag.
Number of subjects: 1036

Group type: EXPERIMENTAL
Intervention: Device-integrated diagnostic-positive patients in the high-risk MAGGIC cohort.
Number of subjects: 1036

Group type: EXPERIMENTAL
Intervention: Combination of clinical and device diagnostic parameters.
Number of subjects: 1036
Study: 31291850

Group type: EXPERIMENTAL
Intervention: DSC-PWI
Number of subjects: 221

Group type: COMPARATOR
Intervention: T2*GRE
Number of subjects: 221
Study: 31291985

Group type: EXPERIMENTAL
Intervention: Selinexor combined with high-dose cytarabine (HiDAC) and mitoxantrone (Mito)
Number of subjects: 26
Study: 31292118

Group type: EXPERIMENTAL
Intervention: POD24 (progression of disease within 24 months from diagnosis)
Number of subjects: 321

Group type: COMPARATOR
Intervention: No POD24
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Subgroup analysis for splenic and extranodal MZLs
Number of subjects: 321
Study: 31292122

Group type: EXPERIMENTAL
Intervention: Sugary drinks consumption (100mL/d increase)
Number of subjects: 101257

Group type: EXPERIMENTAL
Intervention: 100% fruit juice consumption
Number of subjects: 101257

Group type: COMPARATOR
Intervention: Artificially sweetened beverages consumption
Number of subjects: 101257
Study: 31292141

Group type: EXPERIMENTAL
Intervention: Microvascular complications (neuropathy, nephropathy, retinopathy) in patients with DM and HFpEF
Number of subjects: 2800

Group type: EXPERIMENTAL
Intervention: HFpEF
Number of subjects: 2800

Group type: COMPARATOR
Intervention: HFrEF
Number of subjects: 2800